Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18630941 | METHODS OF IDENTIFYING MULTIPLE EPITOPES IN CELLS | April 2024 | August 2024 | Allow | 4 | 0 | 0 | Yes | No |
| 18514645 | DIGITAL ANALYTE ANALYSIS | November 2023 | April 2024 | Allow | 5 | 1 | 1 | No | No |
| 18379589 | METHOD FOR LABELING LIGATION PRODUCTS WITH CELL-SPECIFIC BARCODES II | October 2023 | February 2024 | Allow | 4 | 0 | 0 | Yes | No |
| 18379586 | METHOD FOR LABELING LIGATION PRODUCTS WITH CELL-SPECIFIC BARCODES I | October 2023 | January 2024 | Allow | 3 | 0 | 0 | No | No |
| 18450212 | AP50 POLYMERASES AND USES THEREOF | August 2023 | May 2024 | Allow | 10 | 0 | 0 | No | No |
| 18233221 | Kit for Split-Pool Barcoding Target Molecules That Are In or On Cells or Cell Organelles | August 2023 | November 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18233214 | Barcoded Beads and Method for Making the Same by Split-Pool Synthesis | August 2023 | October 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18134003 | METHODS OF IDENTIFYING MULTIPLE EPITOPES IN CELLS | April 2023 | August 2023 | Allow | 4 | 0 | 0 | No | No |
| 18102056 | METHODS OF IDENTIFYING MULTIPLE EPITOPES IN CELLS | January 2023 | May 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18086369 | METHODS OF IDENTIFYING MULTIPLE EPITOPES IN CELLS | December 2022 | April 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 18086383 | BARCODED BEADS AND METHOD FOR MAKING THE SAME BY SPLIT-POOL SYNTHESIS | December 2022 | April 2023 | Allow | 4 | 0 | 0 | No | No |
| 17984207 | METHODS FOR BARCODING MACROMOLECULES IN INDIVIDUAL CELLS | November 2022 | April 2023 | Allow | 5 | 0 | 0 | No | No |
| 17951003 | KIT FOR SPLIT-POOL BARCODING TARGET MOLECULES THAT ARE IN OR ON CELLS OR CELL ORGANELLES | September 2022 | February 2023 | Allow | 5 | 0 | 0 | No | No |
| 17951013 | METHODS OF IDENTIFYING MULTIPLE EPITOPES IN CELLS | September 2022 | February 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 17951008 | METHODS OF IDENTIFYING MULTIPLE EPITOPES IN CELLS | September 2022 | March 2023 | Allow | 6 | 0 | 0 | Yes | No |
| 17820735 | METHODS FOR DETECTING RNA BINDING PROTEIN COMPLEXES | August 2022 | April 2023 | Allow | 8 | 1 | 1 | No | No |
| 17870697 | METHODS OF IDENTIFYING MULTIPLE EPITOPES IN CELLS | July 2022 | October 2022 | Allow | 3 | 0 | 1 | Yes | No |
| 17870641 | METHODS OF IDENTIFYING MULTIPLE EPITOPES IN CELLS | July 2022 | September 2022 | Allow | 2 | 0 | 0 | Yes | No |
| 17812683 | NUCLEASE-BASED RNA DEPLETION | July 2022 | February 2024 | Allow | 19 | 0 | 0 | Yes | No |
| 17833982 | ASSAY FOR DETECTING HUMAN PAPILLOMA VIRUS (HPV) | June 2022 | February 2024 | Allow | 20 | 0 | 0 | Yes | No |
| 17830121 | Compositions and Methods for Detecting C1orf43 Nucleic Acid | June 2022 | November 2023 | Allow | 17 | 0 | 0 | No | No |
| 17746400 | DRIED COMPOSITIONS CONTAINING FLAP ENDONUCLEASE | May 2022 | December 2023 | Allow | 19 | 0 | 0 | No | No |
| 17743315 | MOLECULAR ANALYSES USING LONG CELL-FREE FRAGMENTS IN PREGNANCY | May 2022 | October 2022 | Allow | 5 | 1 | 0 | Yes | No |
| 17739892 | Multiplexed Kras Mutation Detection Assay | May 2022 | April 2024 | Allow | 23 | 1 | 0 | No | No |
| 17737880 | EXPONENTIAL BASE-3 AND GREATER NUCLEIC ACID AMPLIFICATION WITH REDUCED AMPLIFICATION TIME | May 2022 | May 2024 | Allow | 25 | 0 | 0 | No | No |
| 17735509 | Microfluidic Devices, Solid Supports For Reagents and Related Methods | May 2022 | April 2024 | Allow | 24 | 0 | 1 | No | No |
| 17732384 | AMPLICON RESCUE MULTIPLEX POLYMERASE CHAIN REACTION FOR AMPLIFICATION OF MULTIPLE TARGETS | April 2022 | April 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17697481 | LINEARLY-AMPLIFIED INTERNAL CONTROL FOR NUCLEIC ACID AMPLIFICATION REACTION | March 2022 | October 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17692965 | MULTIPLEX AMPLIFICATION DETECTION ASSAY | March 2022 | October 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17688220 | LINKED LIGATION | March 2022 | August 2023 | Allow | 18 | 0 | 0 | No | No |
| 17684403 | METHODS FOR DETECTING MICROORGANISMS | March 2022 | July 2024 | Abandon | 28 | 1 | 1 | No | No |
| 17676523 | BARCODED MOLECULAR STANDARDS | February 2022 | May 2024 | Allow | 27 | 1 | 1 | No | No |
| 17651657 | NUCLEIC ACID MODIFICATION AND IDENTIFICATION METHOD | February 2022 | September 2023 | Allow | 19 | 0 | 0 | No | No |
| 17672552 | On-Slide Staining by Primer Extension | February 2022 | August 2023 | Allow | 18 | 0 | 0 | No | No |
| 17671789 | COMPOSITIONS AND METHODS FOR THE SELECTIVE DETECTION OF TUMOR-DERIVED VIRAL DNA | February 2022 | October 2023 | Allow | 20 | 0 | 0 | No | No |
| 17581711 | Systems, Methods, and Devices for Sample Collection, Stabilization and Preservation | January 2022 | December 2023 | Abandon | 23 | 1 | 0 | Yes | No |
| 17578942 | METHODS AND SYSTEMS FOR NUCLEIC ACID ANALYSIS AND QUANTIFICATION | January 2022 | February 2024 | Allow | 25 | 0 | 0 | No | No |
| 17573520 | METHODS FOR NESTED PCR AMPLIFICATION | January 2022 | July 2024 | Abandon | 30 | 4 | 1 | Yes | No |
| 17568571 | SOYBEAN TRANSGENIC EVENT MON87751 AND METHODS FOR DETECTION AND USE THEREOF | January 2022 | June 2023 | Allow | 17 | 0 | 0 | No | No |
| 17643398 | DEVICES, SYSTEMS, AND METHODS OF USING SMART FLUIDS TO CONTROL TRANSLOCATION SPEED THROUGH A NANOPORE | December 2021 | November 2023 | Allow | 24 | 0 | 1 | Yes | No |
| 17544669 | METHODS, SYSTEMS, AND COMPOSITIONS FOR COUNTING NUCLEIC ACID MOLECULES | December 2021 | May 2023 | Allow | 18 | 0 | 0 | No | No |
| 17538353 | METHOD FOR MEASUREMENT OF LIVE-CELL PARAMETERS FOLLOWED BY MEASUREMENT OF GENE AND PROTEIN EXPRESSION | November 2021 | January 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17536828 | METHODS FOR PREPARATIVE IN VITRO CLONING | November 2021 | October 2023 | Abandon | 23 | 0 | 1 | No | No |
| 17454082 | Analysis of Chromatin Using a Nicking Enzyme | November 2021 | July 2023 | Allow | 20 | 1 | 0 | No | No |
| 17518213 | METHODS AND SYSTEMS FOR REDUCING ARTIFACTUAL ANTISENSE PRODUCTS | November 2021 | May 2024 | Allow | 30 | 0 | 1 | No | No |
| 17508577 | METHODS FOR NON-INVASIVE PRENATAL PLOIDY CALLING | October 2021 | July 2024 | Abandon | 32 | 2 | 0 | No | No |
| 17502355 | DETERMINING TUMOR ORIGIN | October 2021 | April 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17500858 | NUCLEIC ACID DETECTION COMBINING AMPLIFICATION WITH FRAGMENTATION | October 2021 | December 2023 | Allow | 26 | 1 | 1 | No | No |
| 17500204 | KIT FOR DETERMINING NUCLEIC ACID DEGRADATION | October 2021 | May 2023 | Allow | 19 | 0 | 0 | No | No |
| 17500733 | LINKED PAIRED STRAND SEQUENCING | October 2021 | February 2024 | Allow | 28 | 2 | 0 | No | No |
| 17494745 | METHODS FOR PREPARING A DNA FRACTION FROM A BIOLOGICAL SAMPLE FOR ANALYZING GENOTYPES OF CELL-FREE DNA | October 2021 | May 2022 | Allow | 7 | 1 | 0 | No | No |
| 17448973 | METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING | September 2021 | May 2024 | Abandon | 31 | 0 | 1 | No | No |
| 17448985 | METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING | September 2021 | May 2024 | Abandon | 31 | 0 | 1 | No | No |
| 17480067 | NUCLEIC ACID ENCODING REACTIONS | September 2021 | February 2024 | Allow | 29 | 1 | 1 | No | No |
| 17470896 | SYSTEMS AND METHODS FOR QUALITY CONTROL IN SINGLE CELL PROCESSING | September 2021 | May 2024 | Abandon | 32 | 1 | 1 | Yes | No |
| 17465825 | Molecular Marker C42257 for Rapidly Identifying Genetic Sex of Marsupenaeus japonicus and Applications Thereof | September 2021 | February 2022 | Allow | 5 | 0 | 1 | No | No |
| 17462520 | Methods of Depleting a Target Nucleic Acid in a Sample and Kits for Practicing the Same | August 2021 | May 2024 | Abandon | 32 | 2 | 1 | No | No |
| 17396148 | AMPLIFICATION REPORTER WITH BASE-PAIRING OLIGOMERS | August 2021 | February 2024 | Allow | 31 | 2 | 0 | No | No |
| 17395432 | SYSTEMS AND METHODS OF DIAGNOSING AND CHARACTERIZING INFECTIONS | August 2021 | January 2024 | Allow | 30 | 1 | 1 | No | No |
| 17388769 | OLIGONUCLEOTIDE PRIMERS FOR QUANTIFYING AND/OR DETECTING HUMAN MALE DNA AND KITS CONTAINING THE SAME | July 2021 | January 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17377802 | METHODS FOR NON-INVASIVE PRENATAL PLOIDY CALLING | July 2021 | July 2023 | Abandon | 24 | 5 | 0 | No | No |
| 17378133 | METHODS AND DEVICES FOR NUCLEIC ACIDS SYNTHESIS | July 2021 | August 2023 | Allow | 25 | 0 | 1 | No | No |
| 17374333 | Assays for the Detection of SARS-CoV-2 | July 2021 | October 2022 | Abandon | 15 | 2 | 1 | No | No |
| 17361821 | METHOD FOR NUCLEIC ACID DETECTION BY GUIDING THROUGH A NANOPORE | June 2021 | April 2023 | Allow | 21 | 0 | 1 | No | No |
| 17358105 | BRASSICA GAT EVENT AND COMPOSITIONS AND METHODS FOR THE IDENTIFICATION AND/OR DETECTION THEREOF | June 2021 | January 2023 | Allow | 18 | 0 | 0 | No | No |
| 17417995 | LINKED TARGET CAPTURE | June 2021 | April 2022 | Allow | 10 | 0 | 1 | No | No |
| 17355882 | SYNTHETIC NUCLEIC ACID SPIKE-INS | June 2021 | March 2023 | Allow | 20 | 0 | 0 | No | No |
| 17321301 | DIGITAL TO BIOLOGICAL CONVERTER | May 2021 | January 2023 | Allow | 20 | 0 | 0 | Yes | No |
| 17320052 | PRIMERS FOR IMMUNE REPERTOIRE PROFILING | May 2021 | February 2023 | Allow | 21 | 0 | 1 | No | No |
| 17292955 | DNA-CAGE ERASABLE LABELS FOR FLUORESCENCE-BASED PATHOLOGY | May 2021 | July 2024 | Allow | 38 | 0 | 0 | No | No |
| 17307653 | Kelch Domain Containing 7B (KLHDC7B) Variants And Uses Thereof | May 2021 | January 2023 | Allow | 20 | 0 | 1 | No | No |
| 17306592 | COMPLEX SURFACE-BOUND TRANSPOSOME COMPLEXES | May 2021 | December 2021 | Allow | 7 | 1 | 1 | No | No |
| 17306761 | EXPONENTIAL BASE-GREATER-THAN-2 NUCLEIC ACID AMPLIFICATION | May 2021 | November 2023 | Allow | 31 | 2 | 0 | Yes | No |
| 17244419 | UNIFORM FLUID FILM COOLING DEVICE | April 2021 | November 2023 | Allow | 30 | 0 | 1 | No | No |
| 17244268 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | April 2021 | June 2024 | Allow | 37 | 2 | 1 | Yes | No |
| 17302192 | NUCLEIC ACID AMPLIFICATION | April 2021 | March 2023 | Allow | 23 | 0 | 1 | No | No |
| 17229557 | LIGATION MEDIATED ANALYSIS OF NUCLEIC ACIDS | April 2021 | July 2022 | Abandon | 15 | 2 | 1 | Yes | No |
| 17214485 | METHODS FOR DETECTION OF DONOR-DERIVED CELL-FREE DNA | March 2021 | October 2024 | Abandon | 42 | 2 | 1 | No | No |
| 17213232 | OPERATION METHOD OF MULTIPLEX SLIDE PLATE DEVICE | March 2021 | April 2023 | Allow | 24 | 0 | 0 | No | No |
| 17210637 | METHODS AND REAGENTS FOR THE SPECIFIC AND SENSITIVE DETECTION OF SARS-CoV-2 | March 2021 | August 2023 | Allow | 28 | 2 | 0 | No | No |
| 17206692 | METHODS OF MULTIPLEX dPCR ASSAYS AND SHORT-READ SEQUENCING ASSAYS | March 2021 | October 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17203068 | COMPOSITIONS AND METHODS FOR THE SELECTIVE DETECTION OF TUMOR-DERIVED VIRAL DNA | March 2021 | October 2021 | Allow | 7 | 0 | 1 | No | No |
| 17198064 | METHODS OF IDENTIFYINIG DHA CANOLA NS-B50027-4 | March 2021 | March 2024 | Allow | 36 | 0 | 0 | No | No |
| 17196765 | MOLECULAR ANALYSES USING LONG CELL-FREE FRAGMENTS IN PREGNANCY | March 2021 | February 2022 | Allow | 11 | 1 | 1 | Yes | No |
| 17195613 | HIGH THROUGHPUT AMPLIFICATION AND DETECTION OF SHORT RNA FRAGMENTS | March 2021 | August 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17194850 | METHODS AND DEVICES FOR SEQUENCING NUCLEIC ACIDS IN SMALLER BATCHES | March 2021 | November 2023 | Allow | 32 | 1 | 0 | No | No |
| 17192814 | MASSIVELY PARALLEL SINGLE CELL ANALYSIS | March 2021 | February 2023 | Allow | 24 | 0 | 0 | No | No |
| 17187331 | MULTIPLEXED POLYMERASE CHAIN REACTION IN MICROPIPETTE FORMAT | February 2021 | July 2023 | Allow | 29 | 0 | 1 | No | No |
| 17187227 | SOLID STATE SINGLE CELL METHOD FOR ANALYZING FIXED BIOLOGICAL CELLS | February 2021 | December 2023 | Allow | 33 | 0 | 1 | No | No |
| 17185757 | ON-SLIDE STAINING BY PRIMER EXTENSION | February 2021 | December 2022 | Allow | 21 | 0 | 0 | Yes | No |
| 17183840 | COMPOSITIONS AND KITS FOR MOLECULAR COUNTING | February 2021 | February 2023 | Allow | 24 | 1 | 0 | No | No |
| 17184048 | Barcoding Nucleic Acids | February 2021 | January 2024 | Abandon | 34 | 2 | 0 | No | No |
| 17180627 | BUSINESS FACILITY WITH AN EXTERIOR MICROBIOME | February 2021 | July 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17170541 | METHYLATION ASSAY | February 2021 | February 2023 | Allow | 24 | 1 | 0 | Yes | No |
| 17161923 | DETECTION OF NUCLEIC ACIDS FROM MULTIPLE TYPES OF HUMAN PAPILLOMAVIRUS | January 2021 | January 2023 | Allow | 23 | 0 | 0 | Yes | No |
| 17162093 | PROTEIN AND GENE BIOMARKERS FOR REJECTION OF ORGAN TRANSPLANTS | January 2021 | June 2023 | Allow | 29 | 1 | 0 | No | No |
| 17160329 | NUCLEASE PROFILING SYSTEM | January 2021 | October 2023 | Allow | 33 | 2 | 0 | No | No |
| 17153789 | Endometriosis Classifier | January 2021 | August 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17153309 | METHODS AND COMPOSITIONS FOR NUCLEIC ACID SEQUENCING | January 2021 | July 2023 | Allow | 30 | 1 | 1 | No | No |
| 17146994 | EMULSION BASED DRUG SCREENING | January 2021 | October 2022 | Allow | 21 | 0 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PRIEST, AARON A.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner PRIEST, AARON A works in Art Unit 1637 and has examined 910 patent applications in our dataset. With an allowance rate of 64.8%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 31 months.
Examiner PRIEST, AARON A's allowance rate of 64.8% places them in the 25% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by PRIEST, AARON A receive 1.88 office actions before reaching final disposition. This places the examiner in the 45% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by PRIEST, AARON A is 31 months. This places the examiner in the 54% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +24.6% benefit to allowance rate for applications examined by PRIEST, AARON A. This interview benefit is in the 71% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 18.2% of applications are subsequently allowed. This success rate is in the 17% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 34.5% of cases where such amendments are filed. This entry rate is in the 51% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 109.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 79% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 76.5% of appeals filed. This is in the 68% percentile among all examiners. Of these withdrawals, 74.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 39.8% are granted (fully or in part). This grant rate is in the 29% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.2% of allowed cases (in the 53% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.